This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MiMedx Group Announces Changes To Board Of Directors

KENNESAW, Ga., Sept. 10, 2012 /PRNewswire/ --  MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its Board of Directors has appointed two new members, effective September 5, 2012. The new directors are healthcare executive Charles R. Evans and Neil S. Yeston, M.D., F.A.C.S., a healthcare practitioner, innovator and leader. 

In addition, the Company announced that incumbent directors Kurt M. Eichler and Andrew K. Rooke, Jr ., have resigned from the Board to devote more time to their other interests and pave the way for these two new additions.  Both Mr. Eichler and Mr. Rooke will continue to be available to the MiMedx Board and management on a consultative basis.

"MiMedx is fortunate to have an accomplished Board of Directors with in-depth experience in a wide-range of industries and professions. The addition of Charles Evans and Dr. Neil Yeston will further expand and complement the expertise that our directors already bring to MiMedx," commented Parker H. Petit, the Company's Chairman and Chief Executive Officer. "Each of our new directors is well respected in their field of interest, and together they will provide our board and management team with new insight and perspectives relating to our business."

"I wish to thank Kurt Eichler and Kreamer Rooke who have offered invaluable service to MiMedx over many years. I know the entire Board of Directors joins me in thanking each of them for their many contributions towards the long-term success of MiMedx Group," said Petit.

Both Mr. Evans and Dr. Yeston are Class I Directors who will serve for a term expiring at the 2014 Annual Meeting of Stockholders

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs